89 related articles for article (PubMed ID: 28387912)
21. Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells.
Sun P; Sehouli J; Denkert C; Mustea A; Könsgen D; Koch I; Wei L; Lichtenegger W
J Mol Med (Berl); 2005 Jun; 83(6):457-67. PubMed ID: 15770498
[TBL] [Abstract][Full Text] [Related]
22. Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
Zhao S; Dorn J; Napieralski R; Walch A; Diersch S; Kotzsch M; Ahmed N; Hooper JD; Kiechle M; Schmitt M; Magdolen V
Biol Chem; 2017 Jun; 398(7):765-773. PubMed ID: 27935848
[TBL] [Abstract][Full Text] [Related]
23. Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression.
Xu L; Deng Q; Pan Y; Peng M; Wang X; Song L; Xiao M; Wang Z
Int J Mol Med; 2014 Jan; 33(1):91-6. PubMed ID: 24212330
[TBL] [Abstract][Full Text] [Related]
24. A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer.
Cheng Z; Guo J; Chen L; Luo N; Yang W; Qu X
Oncotarget; 2015 Sep; 6(28):25381-9. PubMed ID: 26299803
[TBL] [Abstract][Full Text] [Related]
25. The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.
Huang S; Qing C; Huang Z; Zhu Y
Diagn Pathol; 2016 Jun; 11(1):49. PubMed ID: 27283598
[TBL] [Abstract][Full Text] [Related]
26. Reduced Klotho expression contributes to poor survival rates in human patients with ovarian cancer, and overexpression of Klotho inhibits the progression of ovarian cancer partly via the inhibition of systemic inflammation in nude mice.
Yan Y; Wang Y; Xiong Y; Lin X; Zhou P; Chen Z
Mol Med Rep; 2017 Apr; 15(4):1777-1785. PubMed ID: 28259911
[TBL] [Abstract][Full Text] [Related]
27. High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer.
Qin L; Li T; Liu Y
PLoS One; 2017; 12(11):e0187385. PubMed ID: 29091960
[TBL] [Abstract][Full Text] [Related]
28. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.
Chao A; Lin CY; Lee YS; Tsai CL; Wei PC; Hsueh S; Wu TI; Tsai CN; Wang CJ; Chao AS; Wang TH; Lai CH
Oncogene; 2012 Feb; 31(6):764-75. PubMed ID: 21725366
[TBL] [Abstract][Full Text] [Related]
29. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
30. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
[TBL] [Abstract][Full Text] [Related]
31. Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.
Zhang J; Yu S; Li Q; Wang Q; Zhang J
Gynecol Oncol; 2022 Mar; 164(3):566-576. PubMed ID: 35042621
[TBL] [Abstract][Full Text] [Related]
32. eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.
Zhang Y; Yu JJ; Tian Y; Li ZZ; Zhang CY; Zhang SF; Cao LQ; Zhang Y; Qian CY; Zhang W; Zhou HH; Yin JY; Liu ZQ
Oncotarget; 2015 Sep; 6(28):25441-51. PubMed ID: 26213845
[TBL] [Abstract][Full Text] [Related]
33. Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer.
Kurita T; Izumi H; Kagami S; Kawagoe T; Toki N; Matsuura Y; Hachisuga T; Kohno K
Cancer Sci; 2012 Feb; 103(2):239-444. PubMed ID: 22098591
[TBL] [Abstract][Full Text] [Related]
34. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells.
Basaki Y; Hosoi F; Oda Y; Fotovati A; Maruyama Y; Oie S; Ono M; Izumi H; Kohno K; Sakai K; Shimoyama T; Nishio K; Kuwano M
Oncogene; 2007 Apr; 26(19):2736-46. PubMed ID: 17072343
[TBL] [Abstract][Full Text] [Related]
35. Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients.
Sinha D; Chong L; George J; Schlüter H; Mönchgesang S; Mills S; Li J; Parish C; Bowtell D; Kaur P;
Clin Cancer Res; 2016 Apr; 22(7):1813-24. PubMed ID: 26589433
[TBL] [Abstract][Full Text] [Related]
36. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer.
Aldovini D; Demichelis F; Doglioni C; Di Vizio D; Galligioni E; Brugnara S; Zeni B; Griso C; Pegoraro C; Zannoni M; Gariboldi M; Balladore E; Mezzanzanica D; Canevari S; Barbareschi M
Int J Cancer; 2006 Oct; 119(8):1920-6. PubMed ID: 16804906
[TBL] [Abstract][Full Text] [Related]
37. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells.
Huang M; Page C; Reynolds RK; Lin J
Gynecol Oncol; 2000 Oct; 79(1):67-73. PubMed ID: 11006034
[TBL] [Abstract][Full Text] [Related]
38. MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
[TBL] [Abstract][Full Text] [Related]
39. High IGF2 expression is associated with poor clinical outcome in human ovarian cancer.
Dong Y; Li J; Han F; Chen H; Zhao X; Qin Q; Shi R; Liu J
Oncol Rep; 2015 Aug; 34(2):936-42. PubMed ID: 26063585
[TBL] [Abstract][Full Text] [Related]
40. Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
Zhang Y; Hua W; Niu LC; Li SM; Wang YM; Shang L; Zhang C; Li WN; Wang R; Chen BL; Xin XY; Zhang YQ; Wang J
Tumour Biol; 2016 Jul; 37(7):9423-31. PubMed ID: 26781874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
